Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

Event-free Survival (EFS) in MATTERHORN: A Randomized, Phase 3 Study of Durvalumab plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Chemotherapy (FLOT) in Resectable Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, Phase 3 IRAKLIA study